Allergy Therapeutics Statistics
Want to see GB:AGY full AI Analyst Report?
Allergy Therapeutics (AGY) Stock Statistics & Valuation Metrics
Total Valuation
Allergy Therapeutics has a market cap or net worth of GBX 88.66M. The enterprise value is GBX 478.24M.
- Market Cap
- GBX 88.66M
- Enterprise Value
- GBX 478.24M
Share Statistics
Allergy Therapeutics has 6,332,530,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 6,332,530,000
- Owned by Insiders
- ―
- Owned by Institutions
- 0.09%
Financial Efficiency
Allergy Therapeutics’s return on equity (ROE) is 4.97 and return on invested capital (ROIC) is -60.36%.
- Return on Equity (ROE)
- 4.97
- Return on Assets (ROA)
- -0.59
- Return on Invested Capital (ROIC)
- -60.36%
- Return on Capital Employed (ROCE)
- -0.64
- Revenue Per Employee
- 102.52K
- Profits Per Employee
- -88.20K
- Employee Count
- 584
- Asset Turnover
- 0.69
- Inventory Turnover
- 2.24
Valuation Ratios
The current PE Ratio of Allergy Therapeutics is -1.59. Allergy Therapeutics’s PEG ratio is 0.18.
- PE Ratio
- -1.59
- PS Ratio
- 1.48
- PB Ratio
- -8.53
- Price to FCF
- -2.39
- Price to Operating Cash Flow
- -2.75
- PEG Ratio
- 0.18
Income Statement
In the last 12 months, Allergy Therapeutics had revenue of 59.87M and earned -51.51M in profits. Earnings per share was -0.01.
- Revenue
- 59.87M
- Gross Profit
- 24.78M
- Operating Income
- -40.98M
- Pretax Income
- -52.41M
- Net Income
- -51.51M
- EBITDA
- -36.34M
- Earnings Per Share (EPS)
- -0.01
Cash Flow
In the last 12 months, operating cash flow was -32.13M and capital expenditures -4.93M, giving a free cash flow of -37.06M billion.
- Operating Cash Flow
- -32.13M
- Free Cash Flow
- -37.06M
- Free Cash Flow per Share
- -0.01
Dividends & Yields
Allergy Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -41.81%
- Earnings Yield
- -58.23%
Stock Price Statistics
- Beta
- 0.96
- 52-Week Price Change
- -83.72%
- 50-Day Moving Average
- 3.99
- 200-Day Moving Average
- 7.45
- Relative Strength Index (RSI)
- 10.72
- Average Volume (3m)
- 858.69K
Important Dates
Allergy Therapeutics upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 13, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Allergy Therapeutics as a current ratio of 2.29, with Debt / Equity ratio of -646.31%
- Current Ratio
- 2.29
- Quick Ratio
- 1.61
- Debt to Market Cap
- 0.15
- Net Debt to EBITDA
- -1.18
- Interest Coverage Ratio
- -5.02
Taxes
In the past 12 months, Allergy Therapeutics has paid -902.00K in taxes.
- Income Tax
- -902.00K
- Effective Tax Rate
- 0.02
Enterprise Valuation
Allergy Therapeutics EV to EBITDA ratio is -3.62, with an EV/FCF ratio of -3.55.
- EV to Sales
- 2.20
- EV to EBITDA
- -3.62
- EV to Free Cash Flow
- -3.55
- EV to Operating Cash Flow
- -4.09
Balance Sheet
Allergy Therapeutics has GBX 24.20M in cash and marketable securities with GBX 67.00M in debt, giving a net cash position of -GBX 42.79M billion.
- Cash & Marketable Securities
- GBX 24.20M
- Total Debt
- GBX 67.00M
- Net Cash
- -GBX 42.79M
- Net Cash Per Share
- -GBX 0.01
- Tangible Book Value Per Share
- GBX 0.00
Margins
Gross margin is 41.39%, with operating margin of -68.45%, and net profit margin of -86.04%.
- Gross Margin
- 41.39%
- Operating Margin
- -68.45%
- Pretax Margin
- -83.62%
- Net Profit Margin
- -86.04%
- EBITDA Margin
- -60.70%
- EBIT Margin
- -68.45%
Analyst Forecast
The average price target for Allergy Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 8.77%
- EPS Growth Forecast
- -7.14%
Scores
- Smart Score
- 4
- AI Score
- 41

